A randomised phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
J Am Acad Dermatol 2024;91:1150–7 doi: 10.1016/j.jaad.2024.07.1521
Lebwohl et al. investigated the efficacy and safety of risankizumab compared with placebo for treating palmoplantar psoriasis. At Wk16, significantly more patients receiving risankizumab achieved palmoplantar Investigator’s Global Assessment (ppIGA) 0/1 and PPASI75. The results were sustained through Wk52 with no new safety signals.
This Phase 3b randomised, double-blind trial included 174 adult patients with
moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement. Participants were randomised 1:1 to risankizumab 150mg or placebo for 16 weeks, followed by open-label risankizumab treatment through Wk52. The study assessed efficacy using ppIGA, PPASI, and static Physician Global Assessment (sPGA) responses, with safety evaluated by TEAEs.
Keywords:
